Trials / Unknown
UnknownNCT05749211
Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
Efficacy and Safety of Huaier Granule in Combination With Nilaparil in First-line Maintenance Therapy in Postoperative Patients With Stage III/IV BRCA Wild-type Ovarian Cancer: a Single-center Prospective, Single-arm Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a single-center, prospective, single-arm clinical trial to evaluate the efficacy and safety of Huaier granules in combination with immunotargeted agents in postoperative patients with ovarian cancer.
Detailed description
Primary objective : 1\) To evaluate the efficacy of Huaier granule combined with immunotargeted drugs in the treatment of postoperative ovarian cancer patients Secondary objectives: 1)To analyze the safety of Huaier granule in the treatment of postoperative ovarian cancer patients; 2)2) To analyze the influence of Huaier granule on postoperative quality of life of patients with ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Huaier granule | Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2023-12-01
- Completion
- 2025-12-01
- First posted
- 2023-03-01
- Last updated
- 2023-05-16
Source: ClinicalTrials.gov record NCT05749211. Inclusion in this directory is not an endorsement.